Presentation is loading. Please wait.

Presentation is loading. Please wait.

Early lesion analysis to identify potential targets for therapeutic intervention. Early lesion analysis to identify potential targets for therapeutic intervention.

Published byZsófia Hegedűs Modified over 5 years ago

Similar presentations

Presentation on theme: "Early lesion analysis to identify potential targets for therapeutic intervention. Early lesion analysis to identify potential targets for therapeutic intervention."— Presentation transcript:

1 Early lesion analysis to identify potential targets for therapeutic intervention.
Early lesion analysis to identify potential targets for therapeutic intervention. (A). KrasG12V-driven early lung lesions (≤500 cells) were microdissected and analysed by standard Affymetrix technology. Tumour signatures clustered in two distinct groups, one of which resembled normal lung alveolar cells (H1) and the other one aggressive murine and human lung adenocarcinoma (H2). The top-scoring gene of the H2 signature was the Discoidin Domain Receptor 1 (DDR1). (B). KrasG12V-driven lung tumours (10 months after Ad-Cre infection) were isolated and analysed by standard Affymetrix technology. Tumour signatures clustered in two distinct groups, T1 and T2. H2 signature was diluted in the T2 signature. (C). KrasG12V;Ddr1−/− mice survived longer and have reduced tumour size/number compared to control KrasG12V; Ddr1+/+ mice. Chiara Ambrogio et al. ESMO Open 2016;1:e000076 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "Early lesion analysis to identify potential targets for therapeutic intervention. Early lesion analysis to identify potential targets for therapeutic intervention."

Similar presentations

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
The chimeric Trk protein, composed by the TK domain with ATPase activity and a TM loop along with a fusion partner. The chimeric Trk protein, composed.

The chimeric Trk protein, composed by the TK domain with ATPase activity and a TM loop along with a fusion partner. The chimeric Trk protein, composed.
Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.

Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.
Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.

A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.
Progesterone receptor nuclear morphology patterns in breast cancer.

Progesterone receptor nuclear morphology patterns in breast cancer.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.
Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)

Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.
Therapeutic validation in orthotopic lung PDX. (A).

Therapeutic validation in orthotopic lung PDX. (A).
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.
Waterfall plot of the best per cent change from baseline in SLD of target lesions in 33 patients. Waterfall plot of the best per cent change from baseline.

Waterfall plot of the best per cent change from baseline in SLD of target lesions in 33 patients. Waterfall plot of the best per cent change from baseline.
Flow chart of the used methodology adapted from Moher et al

Flow chart of the used methodology adapted from Moher et al
Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.
Detection rate for EGFR mutations in cfDNA.

Detection rate for EGFR mutations in cfDNA.
Waterfall plots of the best per cent change from baseline in sum of longest diameters (SLD) for target lesions. Waterfall plots of the best per cent change.

Waterfall plots of the best per cent change from baseline in sum of longest diameters (SLD) for target lesions. Waterfall plots of the best per cent change.
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
PRISMA study flow diagram

PRISMA study flow diagram

Similar presentations

Ads by Google